JPRN-jRCT2080224603已完成3 期
An Open-Label, Single-arm, Multi-Center, Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Japanese Subjects with Moderate-to-Severe Psoriasis
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •a. For participants with plaque psoriasis:
- •i. Stable plaque psoriasis for at least 6 months
- •ii. Moderate to severe disease
- •iii. Candidate for phototherapy or systemic therapy
- •b. Additional protocol-specified inclusion criteria apply for subjects with psoriatic arthritis, erythrodermic psoriasis, or generalized pustular psoriasis
排除标准
- •1.Guttate, inverse, or drug-induced psoriasis at Screening or Baseline
- •2.History of recent infection
- •3.Prior exposure to BMS-986165
研究者
相似试验
进行中（未招募）
1 期
A Phase 3, Open-Label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Activity, and Safety of Ravulizumab Administered Subcutaneously in Pediatric Participants (2 to < 18 years of age) with Paroxysmal Nocturnal Hemoglobinuria (PNH) or Atypical Hemolytic Uremic Syndrome (aHUS)Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) or Atypical Hemolytic Uremic Syndrome (aHUS)MedDRA version: 20.1Level: LLTClassification code: 10079841Term: Atypical hemolytic uremic syndrome Class: 10005329MedDRA version: 21.1Level: LLTClassification code: 10055629Term: Paroxysmal nocturnal hemoglobinuria Class: 10038359CTIS2022-502335-19-00Alexion Pharmaceuticals Inc.22
进行中（未招募）
1 期
A Phase 3b, Open-Label, Single Arm, Multi-Centre Study to Assess the Safety and Efficacy of Pegvaliase (BMN 165) Treatment in adults With Phenylketonuria Not Controlled With Current ManagementEUCTR2018-000648-25-DEBioMarin Pharmaceutical Inc.85
进行中（未招募）
1 期
A Phase 3b, Open-Label, Single Arm, Multi-Centre Study to Assess the Safety and Efficacy of Pegvaliase (BMN 165) Treatment in adults With Phenylketonuria Not Controlled With Current ManagementEUCTR2018-000648-25-NLBioMarin Pharmaceutical Inc.85
进行中（未招募）
1 期
A Phase 3b, Open-Label, Single Arm, Multi-Centre Study to Assess the Safety and Efficacy of Pegvaliase (BMN 165) Treatment in adults With Phenylketonuria Not Controlled With Current ManagementPhenylketonuria (PKU)MedDRA version: 20.0 Level: LLT Classification code 10034873 Term: Phenylketonuria (PKU) System Organ Class: 100000004850EUCTR2018-000648-25-FRBioMarin Pharmaceutical Inc.76
进行中（未招募）
3 期
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Japanese Adults With HypoparathyroidismHypoparathyroidismJPRN-jRCT2051210058Sibley Christopher12